Cataract Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cataract Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Abstract
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cataract - Drugs In Development, 2022, provides an overview of the Cataract (Ophthalmology) pipeline landscape.
Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. Risk factors include age, diabetes, drinking excessive amounts of alcohol, high blood pressure, obesity and smoking.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cataract - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cataract (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cataract (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Cataract and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Cataract (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cataract (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Cataract (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cataract (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cataract (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cataract (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cataract (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cataract (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Content
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cataract - Overview
Cataract - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cataract - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cataract - Companies Involved in Therapeutics Development
Calpain Therapeutics Pty Ltd
Caregen Co Ltd
Cellix Bio Pvt Ltd
CGeneTech (Suzhou China) Co Ltd
Genisphere LLC
Kubota Vision Inc
Nacuity Pharmaceuticals Inc
Optus Pharmaceutical Co Ltd
Plex Pharmaceuticals Inc
Reven Holdings Inc
ViewPoint Therapeutics Inc
Vitreo Pharma Inc
Cataract - Drug Profiles
CAP-1160 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CAP-4196 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CAT-811 - Drug Profile
Product Description
Mechanism Of Action
Cataract - Drug Profile
Product Description
Mechanism Of Action
CGT-1507 - Drug Profile
Product Description
Mechanism Of Action
CLXOPH-65 - Drug Profile
Product Description
Mechanism Of Action
DHPNP-06 - Drug Profile
Product Description
Mechanism Of Action
GL-249 - Drug Profile
Product Description
Mechanism Of Action
NPI-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RPEC-1007a - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Presbyopia and Cataract - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit NFkB for Ophthalmology, Oncology, Dermatology, Immunology and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
tafamidis - Drug Profile
Product Description
Mechanism Of Action
History of Events
VP-1001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VT-1001 - Drug Profile
Product Description
Mechanism Of Action
ZOC-2017217 - Drug Profile
Product Description
Mechanism Of Action
Cataract - Dormant Projects
Cataract - Discontinued Products
Cataract - Product Development Milestones
Featured News & Press Releases
May 01, 2018: ViewPoint Appoints Dr. Robert Kim as Chief Medical Officer
Sep 07, 2016: Plex Pharmaceuticals awarded $299,173 NIH Phase I SBIR grant funding to find non-surgical treatments for Cataracts
May 13, 2012: Calpain Therapeutics Wins Commercialisation Australia Grant To Progress Anti-Cataract Programme
Sep 04, 2011: New Drug Eyes Way To Beat Cataracts
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Cataract, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Cataract - Pipeline by Calpain Therapeutics Pty Ltd, 2022
Cataract - Pipeline by Caregen Co Ltd, 2022
Cataract - Pipeline by Cellix Bio Pvt Ltd, 2022
Cataract - Pipeline by CGeneTech (Suzhou China) Co Ltd, 2022
Cataract - Pipeline by Genisphere LLC, 2022
Cataract - Pipeline by Kubota Vision Inc, 2022
Cataract - Pipeline by Nacuity Pharmaceuticals Inc, 2022
Cataract - Pipeline by Optus Pharmaceutical Co Ltd, 2022
Cataract - Pipeline by Plex Pharmaceuticals Inc, 2022
Cataract - Pipeline by Reven Holdings Inc, 2022
Cataract - Pipeline by ViewPoint Therapeutics Inc, 2022
Cataract - Pipeline by Vitreo Pharma Inc, 2022
Cataract - Dormant Projects, 2022
Cataract - Discontinued Products, 2022
List of Figures
Number of Products under Development for Cataract, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cataract - Drugs In Development, 2022, provides an overview of the Cataract (Ophthalmology) pipeline landscape.
Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. Risk factors include age, diabetes, drinking excessive amounts of alcohol, high blood pressure, obesity and smoking.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cataract - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cataract (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cataract (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Cataract and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Cataract (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cataract (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Cataract (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cataract (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cataract (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cataract (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cataract (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cataract (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cataract - Overview
Cataract - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cataract - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cataract - Companies Involved in Therapeutics Development
Calpain Therapeutics Pty Ltd
Caregen Co Ltd
Cellix Bio Pvt Ltd
CGeneTech (Suzhou China) Co Ltd
Genisphere LLC
Kubota Vision Inc
Nacuity Pharmaceuticals Inc
Optus Pharmaceutical Co Ltd
Plex Pharmaceuticals Inc
Reven Holdings Inc
ViewPoint Therapeutics Inc
Vitreo Pharma Inc
Cataract - Drug Profiles
CAP-1160 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CAP-4196 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CAT-811 - Drug Profile
Product Description
Mechanism Of Action
Cataract - Drug Profile
Product Description
Mechanism Of Action
CGT-1507 - Drug Profile
Product Description
Mechanism Of Action
CLXOPH-65 - Drug Profile
Product Description
Mechanism Of Action
DHPNP-06 - Drug Profile
Product Description
Mechanism Of Action
GL-249 - Drug Profile
Product Description
Mechanism Of Action
NPI-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RPEC-1007a - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Presbyopia and Cataract - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit NFkB for Ophthalmology, Oncology, Dermatology, Immunology and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
tafamidis - Drug Profile
Product Description
Mechanism Of Action
History of Events
VP-1001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VT-1001 - Drug Profile
Product Description
Mechanism Of Action
ZOC-2017217 - Drug Profile
Product Description
Mechanism Of Action
Cataract - Dormant Projects
Cataract - Discontinued Products
Cataract - Product Development Milestones
Featured News & Press Releases
May 01, 2018: ViewPoint Appoints Dr. Robert Kim as Chief Medical Officer
Sep 07, 2016: Plex Pharmaceuticals awarded $299,173 NIH Phase I SBIR grant funding to find non-surgical treatments for Cataracts
May 13, 2012: Calpain Therapeutics Wins Commercialisation Australia Grant To Progress Anti-Cataract Programme
Sep 04, 2011: New Drug Eyes Way To Beat Cataracts
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Cataract, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Cataract - Pipeline by Calpain Therapeutics Pty Ltd, 2022
Cataract - Pipeline by Caregen Co Ltd, 2022
Cataract - Pipeline by Cellix Bio Pvt Ltd, 2022
Cataract - Pipeline by CGeneTech (Suzhou China) Co Ltd, 2022
Cataract - Pipeline by Genisphere LLC, 2022
Cataract - Pipeline by Kubota Vision Inc, 2022
Cataract - Pipeline by Nacuity Pharmaceuticals Inc, 2022
Cataract - Pipeline by Optus Pharmaceutical Co Ltd, 2022
Cataract - Pipeline by Plex Pharmaceuticals Inc, 2022
Cataract - Pipeline by Reven Holdings Inc, 2022
Cataract - Pipeline by ViewPoint Therapeutics Inc, 2022
Cataract - Pipeline by Vitreo Pharma Inc, 2022
Cataract - Dormant Projects, 2022
Cataract - Discontinued Products, 2022
List of Figures
Number of Products under Development for Cataract, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Related Report
